2634 Journal of Medicinal Chemistry, 2010, Vol. 53, No. 6
Nuti et al.
(2) Mochizuki, S.; Okada, Y. ADAMs in cancer cell proliferation and
progression. Cancer Sci. 2007, 98, 621–628.
(20) Pruessmeyer, J.; Ludwig, A. The good, the bad and the ugly
substrates for ADAM10 and ADAM17 in brain pathology, in-
flammation and cancer. Semin. Cell Dev. Biol. 2009, 20, 164–174.
(21) Rossello, A.; Nuti, E. Drug design of sulfonylated MMP inhibitors.
In Drug Design of Zinc-Enzyme Inhibitors: Functional, Structural,
and Disease Applications; Wiley Series in Drug Discovery and
Development; Wang, B., series Ed.; John Wiley & Sons, Inc.: New
York, 2009; pp 549-589.
(22) Tamura, Y.; Watanabe, F.; Nakatani, T.; Yasui, K.; Fuji, M.;
Komurasaki, T.; Tsuzuki, H.; Maekawa, R.; Yoshioka, T.;
Kawada, K.; Sugita, K.; Ohtani, M. Highly selective and orally
active inhibitors of type IV collagenase (MMP-9 and MMP-2):
N-sulfonylamino acid derivatives. J. Med. Chem. 1998, 41, 640–
649.
(23) O’Brien, P. M.; Ortwine, D. F.; Pavlovsky, A. G.; Picard, J. A.;
Sliskovic, D. R.; Roth, B. D.; Dyer, R. D.; Johnson, L. L.; Man,
C. F.; Hallak, H. Structure-activity relationships and pharmaco-
kinetic analysis for a series of potent, systemically available bi-
phenylsulfonamide matrix metalloproteinase inhibitors. J. Med.
Chem. 2000, 43, 156–166.
(24) Rossello, A.; Nuti, E.; Orlandini, E.; Carelli, P.; Rapposelli, S.;
Macchia, M.; Minutolo, F.; Carbonaro, L.; Albini, A.; Benelli, R.;
Cercignani, G.; Murphy, G.; Balsamo, A. New N-arylsulfonyl-
N-alkoxyaminoacetohydroxamic acids as selective inhibitors of
gelatinase A (MMP-2). Bioorg. Med. Chem. 2004, 12, 2441–2450.
(25) (a) Rossello, A.; Nuti, E.; Carelli, P.; Orlandini, E.; Macchia, M.;
Nencetti, S.; Zandomeneghi, M.; Balzano, F.; Uccello Barretta, G.;
Albini, A.; Benelli, R.; Cercignani, G.; Murphy, G.; Balsamo, A.
N-i-Propoxy-N-biphenylsulfonylaminobutylhydroxamic acids as
potent and selective inhibitors of MMP-2 and MT1-MMP. Bioorg.
Med. Chem. Lett. 2005, 15, 1321–1326. (b) Nuti, E.; Casalini, F.;
Avramova, S. I.; Santamaria, S.; Cercignani, G.; Marinelli, L.; La Pietra,
V.; Novellino, E.; Orlandini, E.; Nencetti, S.; Tuccinardi, T.; Martinelli,
A.; Lim, N.-H.; Visse, R.; Nagase, H.; Rossello, A. N-O-Isopropyl
Sulfonamido-Based Hydroxamates: Design, Synthesis and Biological
Evaluation of Selective Matrix Metalloproteinase-13 Inhibitors as
Potential Therapeutic Agents for Osteoarthritis. J. Med. Chem. 2009,
52, 4757–4773.
(26) Regarding the debate on the use of hydroxamates as ZBG for
metalloenzymes see: (a) Nuti, E; Panelli, L; Casalini, F; Avramova,
S I; Orlandini, E; Santamaria, S; Nencetti, S; Tuccinardi, T;
Martinelli, A; Cercignani, G; D’Amelio, N; Maiocchi, A; Uggeri,
F; Rossello, A. Design, Synthesis, Biological Evaluation and NMR
Studies of a New Series of Arylsulfones As Selective and Potent
Matrix Metalloproteinase-12 Inhibitors. J. Med. Chem. 2009, 52,
6347–6361. (b) Flipo, M; Charton, J; Hocine, A; Dassonneville, S;
Deprez, B; Deprez-Poulain, R. Hydroxamates: Relationships between
Structure and Plasma Stability. J. Med. Chem. 2009, 52, 6790–6802.
(27) Overall, C. M.; Kleifeld, O. Validating matrix metalloproteinases
as drug targets and antitargets for cancer therapy. Nat. Rev. Cancer
2006, 6, 227–239.
(28) Bertini, I.; Calderone, V.; Fragai, M.; Giachetti, A.; Loconte, M.;
Luchinat, C.; Maletta, M.; Nativi, C.; Yeo, K. J. Exploring the
subtleties of drug-receptor interactions: the case of matrix metal-
loproteinases. J. Am. Chem. Soc. 2007, 129, 2466–2475.
(29) Corrias, M. V.; Gambini, C.; Gregorio, A.; Croce, M.; Barisione,
G.; Cossu, C.; Rossello, A.; Ferrini, S.; Fabbi, M. Different
subcellular localization of ALCAM molecules in neuroblastoma:
association with relapse. Cell. Oncol., accepted for publication.
(30) Rossello, A.; Nuti, E.; Orlandini, E.; Balsamo, A.; Tuccinardi, T.
Compounds having aryl-sulphonamidic structure useful as metal-
loproteases inhibitors. Patent WO2008113756, 2008.
(31) (a) Rossello, A.; Nuti, E.; Maresca, A. ADAMs and ADAMTs
Selective Synthetic Inhibitors. In Drug Design of Zinc-Enzyme
Inhibitors: Functional, Structural, and Disease Applications; Wiley
Series in Drug Discovery and Development; Wang, B., deries Ed.; John
Wiley & Sons, Inc.: New York, 2009; pp 591-645; (b) Fisher, J. F.;
Mobashery, S. Recent advances in MMP inhibitor design. Cancer
Metastasis Rev. 2006, 25, 115–136. (c) Georgiadis, D.; Yiotakis, A.
Specific targeting of metzincin family members with small-molecule
inhibitors: progress toward a multifarious challenge. Bioorg. Med.
Chem. 2008, 16, 8781–8794.
(3) Dong, J.; Opresko, L. K.; Dempsey, P. J.; Lauffenburger, D. A.;
Coffey, R. J.; Wiley, H. S. Metalloprotease-mediated ligand release
regulates autocrine signaling through the epidermal growth factor
receptor. Proc. Natl. Acad. Sci. U.S.A. 1999, 96, 6235–6240.
(4) Garton, K. J.; Gough, P. J.; Raines, E. W. Emerging roles for
ectodomain shedding in the regulation of inflammatory responses.
J. Leukocyte Biol. 2006, 79, 1105–1116.
(5) Swart, G. W. M. Activated leukocyte cell adhesion molecule
(CD166/ALCAM): Developmental and mechanistic aspects of
cell clustering and cell migration. Eur. J. Cell Biol. 2002, 81,
313–321.
(6) Nelissen, J. M. D. T.; Peters, I. M.; De Grooth, B. G.; Van Kooyk,
Y.; Figdor, C. G. Dynamic regulation of activated leukocyte cell
adhesion molecule-mediated homotypic cell adhesion through the
actin cytoskeleton. Mol. Biol. Cell 2000, 11, 2057–2068.
(7) Zimmerman, A. W.; Nelissen, J. M.; van Emst-de Vries, S. E.;
Willems, P. H.; de Lange, F.; Collard, J. G.; van Leeuwen, F. N.;
Figdor, C. G. Cytoskeletal restraints regulate homotypic ALCAM-
mediated adhesion through PKCalpha independently of Rho-like
GTPases. J. Cell. Sci. 2004, 117, 2841–2852.
(8) Swart, G. W.; Lunter, P. C.; Kilsdonk, J. W.; Kempen, L. C.
Activated leukocyte cell adhesion molecule (ALCAM/CD166):
signaling at the divide of melanoma cell clustering and cell migra-
tion? Cancer Metastasis Rev. 2005, 24, 223–236.
(9) Bogenrieder, T.; Herlyn, M. Axis of evil: molecular mechanisms of
cancer metastasis. Oncogene. 2003, 22, 6524–6536.
(10) Rosenthal, E. L.; Matrisian, L. M. Matrix metalloproteases in head
and neck cancer. Head Neck 2006, 28, 639–648.
ꢁ
(11) (a) Uchida, N.; Yang, Z.; Combs, J.; Pourquie, O.; Nguyen, M.;
Ramanathan, R.; Fu, J.; Welply, A.; Chen, S.; Weddell, G.;
Sharma, A. K.; Leiby, K. R.; Karagogeos, D.; Hill, B.; Humeau,
L.; Stallcup, W. B.; Hoffman, R.; Tsukamoto, A. S.; Gearing,
ꢁ
D. P.; Peault, B. The characterization, molecular cloning and
expression of a novel hematopoietic cell antigen from CD34þ
human bone marrow cells. Blood 1997, 89, 2706–2716. (b)
Van Kempen, L. C.; Nelissen, J. M.; Degen, W. G.; Torensma, R.;
Weidle, U. H.; Bloemers, H. P.; Figdor, C. G.; Swart, G. W. Molecular
basis for the homophilic activated leukocyte cell adhesion molecule
(ALCAM)-ALCAM interaction. J. Biol. Chem. 2001, 276, 25783–
25790.
(12) Ofori-Acquah, S. F.; King, J. A. Activated leukocyte cell adhesion
molecule: a new paradox in cancer. Transl. Res. 2008, 151, 122–128.
(13) Piazza, T.; Cha, E.; Bongarzone, I.; Canevari, S.; Bolognesi, A.;
Polito, L.; Bargellesi, A.; Sassi, F.; Ferrini, S.; Fabbi, M. Inter-
nalization and recycling of ALCAM/CD166 detected by a fully
human single chain recombinant antibody. J. Cell Sci. 2005, 118,
1515–1525.
(14) Rosso, O.; Piazza, T.; Bongarzone, I.; Rossello, A.; Mezzanzanica,
D.; Canevari, S.; Orengo, A. M.; Puppo, A.; Ferrini, S.; Fabbi, M.
The ALCAM shedding by the metalloprotease ADAM17/TACE is
a tyrosine kinase-inducible process involved in motility of ovarian
carcinoma cells. Mol Cancer Res. 2007, 5, 1246–1253.
(15) MacPherson, L. J; Bayburt, E. K.; Capparelli, M. P.; Carroll, B. J.;
Goldstein, R.; Justice, M. R.; Zhu, L. J.; Hu, S. I.; Melton, R. A.;
Fryer, L.; Goldberg, R. L.; Doughty, J. R.; Spirito, S.; Blancuzzi,
V.; Wilson, D.; O’Byrne, E. M.; Ganu, V.; Parker, D. T. Discovery
of CGS 27023A, a non-peptidic, potent, and orally active strome-
lysin inhibitor that blocks cartilage degradation in rabbits. J. Med.
Chem. 1997, 40, 2525–2532.
(16) Mezzanzanica, D.; Fabbi, M.; Bagnoli, M.; Staurengo, S.; Losa,
M.; Balladore, E.; Alberti, P.; Lusa, L.; Ditto, A.; Ferrini, S.;
Pierotti, M. A.; Barbareschi, M.; Pilotti, S.; Canevari, S. Sub-
cellular localization of activated cell adhesion molecule is a mole-
cular predictor of survival in ovarian carcinoma patients. Clin.
Cancer Res. 2008, 14, 1726–1733.
(17) Bech-Serra, J. J.; Santiago-Josefat, B.; Esselens, C.; Saftig, P.;
Baselga, J.; Arribas, J.; Canals, F. Proteomic Identification of
Desmoglein 2 and Activated Leukocyte Cell Adhesion Molecule
as Substrates of ADAM17 and ADAM10 by Difference Gel
Electrophoresis. Mol. Cell Biol. 2006, 26, 5086–5095.
(18) Maretzky, T.; Schulte, M.; Ludwig, A.; Rose-John, S.; Blobel, C.;
Hartmann, D.; Altevogt, P.; Saftig, P.; Reiss, K. L1 is sequentially
processed by two differently activated metalloproteases and pre-
senilin/gamma-secretase and regulates neural cell adhesion, cell
migration, and neurite outgrowth. Mol. Cell. Biol. 2005, 25, 9040–
9045.
(19) Santiago-Josefat, B.; Esselens, C.; Bech-Serra, J. J.; Arribas, J.
Post-transcriptional up-regulation of ADAM17 upon epidermal
growth factor receptor activation and in breast tumors. J. Biol.
Chem. 2007, 282, 8325–8331.
(32) (a) Kimura, T.; Miyazaki, S.; Ueda, K.; Tanzawa, K.; Ushiyama,
S.; Takasaki, W. Sulfonamide derivatives. Patent WO 9951572 A1,
1999. (b) Kukkola, P. J.; Robinson, L. A.; Nakajima, M.; Sakaki, J.
Sulfonylamino acid and sulfonylamino hydroxamic acid derivatives.
U.S. Patent US 6277987 B1, 2001. (c) Heintz, R. M.; Getman, D. P.;
McDonald, J. J.; DeCrescenzo, J. A.; Howard, S. Amidoaromatic ring
sulfonamide hydroxamic acid compounds. Patent WO 9839329 A1,
1998. (d) Levin, J. I.; Chen, J. M.; Cole, D. C. Acetylenic R-amino
acid-based sulfonamide hydroxamic acid TACE inhibitors. Patent
WO 0044709 A2, 2000. (e) Levin, J. I.; Chen, J. M.; Cole, D. C.;